Enanta Pharmaceuticals (ENTA) Q1 2024 Earnings
ENTA·Reported May 6, 2024·After market close
Enanta Pharmaceuticals reported Q1 2024 revenue of $17.1M, beat analyst consensus of $16.5M by $534.0K. Diluted EPS came in at $-1.47, missed the $-1.26 consensus by $0.21.
Revenue
$17.1Mbeat by $534.0K
Consensus: $16.5MDiluted EPS
$-1.47missed by $0.21
Consensus: $-1.26
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Enanta Pharmaceuticals's Q1 2024 earnings report.
Enanta Pharmaceuticals (ENTA) reported Q1 2024 earnings on May 6, 2024 after market close.
Enanta Pharmaceuticals reported revenue of $17.1M and diluted EPS of $-1.47 for Q1 2024.
Revenue beat the consensus estimate of $16.5M by $534.0K. EPS missed the consensus estimate of $-1.26 by $0.21.
You can read the 10-Q periodic report (0000950170-24-055581) directly on SEC EDGAR. The filing index links above go to sec.gov.